Phil Chapman
Research Subjects
Phil Chapman has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Nathan Anthony Johnson
Charles Perkins Centre, University of Sydney, Australia; Discipline of Exercise and Sport Science, University of Sydney, Australia
14 shared publications - Andrew M. Hudson
The Christie NHS Foundation Trust, Manchester, United Kingdom
10 shared publications - Andrew Victor Biankin
Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow
10 shared publications - Crispin J. Miller
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
10 shared publications Eleanor W. Trotter
10 shared publications- John Brognard
Department of Surgery, Pharmacology, and Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
10 shared publications
Latest Publications
- 28 February 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 67 (6) , 450-458
Sensorineural and Peripheral Vascular Responses Induced by Exposure to High-Frequency Vibration
Background: Dentists, dental hygienist, and veterinary technicians using drills, scalers, and polishers are at risk of developing sensorineural deficits in the fingers and hands. The goal of this study was to determine whether exposure to high-frequency vibration contributed to changes in sensory function. Methods: The tails of rats were exposed to vibration at 1250 Hz (constant acceleration of 49 m/s2) for 4 hours per day, for 10 days. The effects on sensory nerve function and vascular function were measured. Results: Vibration increased sensitivity to applied pressure and to transcutaneous electrical stimulation at 2000 and 250 Hz. It also resulted in a reduction in blood flow and myogenic tone. Conclusions: Exposure to high-frequency vibration has detrimental effects on both peripheral sensorineural and vascular function.
- 28 February 2025
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 67 (6) , 450-458
Sensorineural and Peripheral Vascular Responses Induced by Exposure to High-Frequency Vibration
Background: Dentists, dental hygienist, and veterinary technicians using drills, scalers, and polishers are at risk of developing sensorineural deficits in the fingers and hands. The goal of this study was to determine whether exposure to high-frequency vibration contributed to changes in sensory function. Methods: The tails of rats were exposed to vibration at 1250 Hz (constant acceleration of 49 m/s2) for 4 hours per day, for 10 days. The effects on sensory nerve function and vascular function were measured. Results: Vibration increased sensitivity to applied pressure and to transcutaneous electrical stimulation at 2000 and 250 Hz. It also resulted in a reduction in blood flow and myogenic tone. Conclusions: Exposure to high-frequency vibration has detrimental effects on both peripheral sensorineural and vascular function.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery
Cancer genome sequencing is being used at an increasing rate to identify actionable driver mutations that can inform therapeutic intervention strategies. A comparison of two of the most prominent cancer genome sequencing databases from different institutes (Cancer Cell Line Encyclopedia and Catalogue of Somatic Mutations in Cancer) revealed marked discrepancies in the detection of missense mutations in identical cell lines (57.38% conformity). The main reason for this discrepancy is inadequate sequencing of GC-rich areas of the exome. We have therefore mapped over 400 regions of consistent inadequate sequencing (cold-spots) in known cancer-causing genes and kinases, in 368 of which neither institute finds mutations. We demonstrate, using a newly identified PAK4 mutation as proof of principle, that specific targeting and sequencing of these GC-rich cold-spot regions can lead to the identification of novel driver mutations in known tumor suppressors and oncogenes. We highlight that cross-referencing between genomic databases is required to comprehensively assess genomic alterations in commonly used cell lines and that there are still significant opportunities to identify novel drivers of tumorigenesis in poorly sequenced areas of the exome. Finally, we assess other reasons for the observed discrepancy, such as variations in dbSNP filtering and the acquisition/loss of mutations, to give explanations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor reproducibility of data. Cancer Res; 74(22); 6390–6. ©2014 AACR.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery
Cancer genome sequencing is being used at an increasing rate to identify actionable driver mutations that can inform therapeutic intervention strategies. A comparison of two of the most prominent cancer genome sequencing databases from different institutes (Cancer Cell Line Encyclopedia and Catalogue of Somatic Mutations in Cancer) revealed marked discrepancies in the detection of missense mutations in identical cell lines (57.38% conformity). The main reason for this discrepancy is inadequate sequencing of GC-rich areas of the exome. We have therefore mapped over 400 regions of consistent inadequate sequencing (cold-spots) in known cancer-causing genes and kinases, in 368 of which neither institute finds mutations. We demonstrate, using a newly identified PAK4 mutation as proof of principle, that specific targeting and sequencing of these GC-rich cold-spot regions can lead to the identification of novel driver mutations in known tumor suppressors and oncogenes. We highlight that cross-referencing between genomic databases is required to comprehensively assess genomic alterations in commonly used cell lines and that there are still significant opportunities to identify novel drivers of tumorigenesis in poorly sequenced areas of the exome. Finally, we assess other reasons for the observed discrepancy, such as variations in dbSNP filtering and the acquisition/loss of mutations, to give explanations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor reproducibility of data. Cancer Res; 74(22); 6390–6. ©2014 AACR.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery
Cancer genome sequencing is being used at an increasing rate to identify actionable driver mutations that can inform therapeutic intervention strategies. A comparison of two of the most prominent cancer genome sequencing databases from different institutes (Cancer Cell Line Encyclopedia and Catalogue of Somatic Mutations in Cancer) revealed marked discrepancies in the detection of missense mutations in identical cell lines (57.38% conformity). The main reason for this discrepancy is inadequate sequencing of GC-rich areas of the exome. We have therefore mapped over 400 regions of consistent inadequate sequencing (cold-spots) in known cancer-causing genes and kinases, in 368 of which neither institute finds mutations. We demonstrate, using a newly identified PAK4 mutation as proof of principle, that specific targeting and sequencing of these GC-rich cold-spot regions can lead to the identification of novel driver mutations in known tumor suppressors and oncogenes. We highlight that cross-referencing between genomic databases is required to comprehensively assess genomic alterations in commonly used cell lines and that there are still significant opportunities to identify novel drivers of tumorigenesis in poorly sequenced areas of the exome. Finally, we assess other reasons for the observed discrepancy, such as variations in dbSNP filtering and the acquisition/loss of mutations, to give explanations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor reproducibility of data. Cancer Res; 74(22); 6390–6. ©2014 AACR.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery
Cancer genome sequencing is being used at an increasing rate to identify actionable driver mutations that can inform therapeutic intervention strategies. A comparison of two of the most prominent cancer genome sequencing databases from different institutes (Cancer Cell Line Encyclopedia and Catalogue of Somatic Mutations in Cancer) revealed marked discrepancies in the detection of missense mutations in identical cell lines (57.38% conformity). The main reason for this discrepancy is inadequate sequencing of GC-rich areas of the exome. We have therefore mapped over 400 regions of consistent inadequate sequencing (cold-spots) in known cancer-causing genes and kinases, in 368 of which neither institute finds mutations. We demonstrate, using a newly identified PAK4 mutation as proof of principle, that specific targeting and sequencing of these GC-rich cold-spot regions can lead to the identification of novel driver mutations in known tumor suppressors and oncogenes. We highlight that cross-referencing between genomic databases is required to comprehensively assess genomic alterations in commonly used cell lines and that there are still significant opportunities to identify novel drivers of tumorigenesis in poorly sequenced areas of the exome. Finally, we assess other reasons for the observed discrepancy, such as variations in dbSNP filtering and the acquisition/loss of mutations, to give explanations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor reproducibility of data. Cancer Res; 74(22); 6390–6. ©2014 AACR.